Article
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Bulletin du cancer - 1 Jun 2014
Boyer Jean-Christophe, Etienne-Grimaldi Marie-Christine, Thomas Fabienne, Quaranta Sylvie, Picard Nicolas, Loriot Marie-Anne, Poncet Delphine, Gagnieu Marie-Claude, Ged Cécile, Broly Franck, Le Morvan Valérie, Bouquié Régis, Gaub Marie-Pierre, Philibert Laurent, Ghiringhelli François, Le Guellec Chantal
Abstract excerpt
Irinotecan is a cytotoxic agent administered by IV infusion in the treatment of advanced colorectal cancer. Its anticancer activity results from its bioactivation into SN-38 metabolite, which is cleared through glucuronidation by the hepatic enzyme uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). In the general population, there is wide inter-subject variability in UGT1A1 enzyme activity related to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.